MyHealthVerse’s Post

What if I told you we could potentially develop a drug addiction treatment using #LPS? 💊 You read that right! At LPS-BioSciences we can extract and characterize LPS from any #Gram-negative bacterium including #Klebsiella oxytoca, which has been shown to potentially reduce #METH cravings! 👩🔬 A March 2023 study suggests that #LPS can reduce #methamphetamine cravings by modulating microglia, the brain's primary immune cells, highlighting the gut-brain axis's significance in addiction #therapy. 🦠 These findings suggest we can develop novel, non-invasive treatments for substance abuse using LPS, opening new avenues for reducing relapse rates and improving long-term recovery outcomes. 📚 Thanks to the authors of this article: #Gut-derived #bacterial LPS attenuates incubation of methamphetamine craving via modulating microglia for this study. ➡ To learn more about LPS extraction for drug development follow this link: https://lnkd.in/e2GRqnbV

Do ECS Variants Affect Personality and Alcohol Addiction? Emerging evidence highlights the endocannabinoid system's crucial role in brain reward mechanisms and addiction. ➡️ Endocannabinoids that signal through the cannabinoid-1 receptor, encoded by the CNR1 gene, are implicated in the addictive effects of alcohol. ➡️ A longitudinal Swedish study with 2,915 participants indicates that a particular genotype of the CB1 receptor may influence both personality and alcohol consumption. Researchers from the Department of Public Health Sciences, Stockholm University, Sweden note that their findings support the idea that the endocannabinoid system can affect alcohol intake behaviors, especially when interacting with life adversities. ✅ Authors state that “their study supports the notion that the ECS can affect alcohol intake behaviors by interacting with life adversities.” Source: Bornscheuer L, Lundin A, Forsell Y, Lavebratt C, Melas PA. The cannabinoid receptor-1 gene interacts with stressful life events to increase the risk for problematic alcohol use. Sci Rep. 2022 Mar 23;12(1):4963. doi: 10.1038/s41598-022-08980-w. PMID: 35322131; PMCID: PMC8941304.

Dr. Marc Siegel has recently shared insights on the potential of medications like Ozempic and Wegovy in addressing alcohol abuse. These medications, primarily used for diabetes and obesity, belong to a class known as GLP-1s, or glucagon-like peptide-1 receptor agonists. Dr. Siegel highlights research indicating that GLP-1s may help reduce cravings for addictive substances, including […]

Study shows GLP-1 agonists lower AUD-related hospitalization risks more than AUD meds like naltrexone. Semaglutide led with a 36% reduced risk. Exciting potential, but trials will clarify their role in addiction treatment. https://lnkd.in/e7c94HFf via @@psychtimes

Kratom addictive? 🍃”with little to no addiction potential demonstrated in pre-clinical studies”🍃 Receptor Selectivity and Therapeutic Potential of Kratom in Substance Use Disorders “These therapeutic uses have been hypothesized to be a result of biased signaling at opioid receptors and the poly-pharmacology of the alkaloids at opioid and adrenergic receptors, with little to no addiction potential demonstrated in pre-clinical studies. Thus, the present review highlights the most recent findings on receptor binding and preclinical evidence to explore the use of kratom and its alkaloids as potentially effective pharmacotherapies for OUD and possible other SUDs.” https://lnkd.in/gCttmzre

CURE GABA-A | Did you know? GABAAR are key to how our brains process alcohol. These receptors regulate GABA, the brain’s main calming neurotransmitter, which is why alcohol often makes people feel relaxed. But here’s the interesting part: variations in certain GABAAR subunits, like GABRA2, GABRA4, and GABRD, can make some people more sensitive to alcohol’s effects or increase the risk of developing a dependency. This means our brain chemistry plays a bigger role in alcohol use than we often realize. Research shows that alcohol dependency isn’t just about behavior, it’s deeply tied to biology. By understanding how GABAARs influence alcohol’s effects, scientists are uncovering new ways to address dependency and support recovery. Why Target GABAARs with Gene Therapy? GABAARs sit at the intersection of many neurological and psychiatric conditions. By correcting the underlying dysfunction in specific subunits: Addiction: Could be addressed by rebalancing reward pathways and reducing substance-induced GABAAR hypersensitivity. Epilepsy: Could be managed by restoring inhibitory signaling to prevent hyperexcitability. If you know someone struggling with dependency, please consider donating generously. Your support can help fund critical research and pave the way toward groundbreaking treatments to address the root causes of addiction. Together, we can make a difference. https://lnkd.in/gJiiEFYY #CUREGABAA #AlcoholDependency #BrainScience #SupportResearch #GABAAR #GABA #GABAA #GABRA2 #GABRA4 #GABRD Alcohol and Drug Foundation Alcoholics Anonymous World Services, Inc. Network of Alcohol and other Drugs Agencies (NADA) Alcohol Addiction Treatment Addiction Professionals

An intriguing study reveals that Semaglutide (commonly known as Ozempic or Wegovy) may reduce opioid overdose by 40% and binging of alcohol by 50%. Beyond their weight loss and antidiabetic benefits, these GLP-1 receptor agonists also offer a significant reduction in opioid overdose and alcohol addictions! Study: https://lnkd.in/e4VAqaUn https://lnkd.in/e7MD8MuQ. https://lnkd.in/g6J-T_jM #semaglutide #opioid overdose #GLP-1 receptor agonists #ozempic #wegovy #weightloss

🌟 Our CEO Featured in Scientific American! 🌟 Our CEO, Ana Moreno, was recently interviewed by Scientific American for an insightful article on Vertex’s Suzetrigine and other novel pain medications that target sodium channels and represent a shift away from opioids. This advancement has revitalized the pain therapeutics field, and Navega Therapeutics is leading the charge in developing next-generation pain treatments. By leveraging cutting-edge AI-enabled epigenetic tools to suppress the genes responsible for chronic pain, Navega Therapeutics is at the forefront of developing these next-generation pain treatments. Our ultimate goal is to create long-lasting, non-addictive therapies that can one day replace opioids. With over 51 million Americans suffering from chronic pain, the need for innovative solutions has never been greater. We are proud to contribute to this critical area of research and are committed to transforming the future of pain management. A big thank you to Marla Broadfoot at Scientific American for highlighting the work we're doing at Navega Therapeutics. Read the full article here: https://lnkd.in/g3mkr5St #PainManagement #GeneTherapy #Epigenetics #NavegaTherapeutics #Innovation #ChronicPain #ScientificAmerican

Kratom🍃”with little to no addiction potential demonstrated in pre-clinical studies” Receptor Selectivity and Therapeutic Potential of Kratom in Substance Use Disorders “These therapeutic uses have been hypothesized to be a result of biased signaling at opioid receptors and the poly-pharmacology of the alkaloids at opioid and adrenergic receptors, with little to no addiction potential demonstrated in pre-clinical studies. Thus, the present review highlights the most recent findings on receptor binding and preclinical evidence to explore the use of kratom and its alkaloids as potentially effective pharmacotherapies for OUD and possible other SUDs.” https://lnkd.in/gCttmzre